OR WAIT null SECS
On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.
October 26, 2026
Video
In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.
October 22, 2026
Article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
August 05, 2026
FDA approval is based on phase 3 FirstLight and RadiantLight trials, the first therapy to directly restore orexin signaling in adults with NT1.
May 28, 2026
Oren Cohen, MD, discusses his research and points toward more clinically deployable cardiovascular risk tools for patients with OSA.
April 14, 2026
Wescott discusses ADAA 2026 findings linking sleeping less than usual to next-day depression in high-risk youth, with interpersonal reactivity emerging as a potential mechanism.
April 13, 2026
Schneider discusses her analysis of the FINEARTS-HF trial, noting the apparent efficacy of finerenone regardless of sleep apnea presence.
February 27, 2026
Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.
Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years
February 14, 2026
Stay updated with the latest healthcare breakthroughs, FDA actions and new phase 2 and 3 data, in this week’s essential news roundup.
February 10, 2026
FDA grants Priority Review for Takeda’s oveporexton, an oral orexin agonist for narcolepsy type 1, showing near-normal symptom control in phase 3.